Non organ based laboratory markers in systemic sclerosis.

Area of Science:

• Immunology
• Rheumatology
• Cell Biology

Background:

• Systemic sclerosis (SSc) is a complex autoimmune disease characterized by inflammation, fibrosis, and vascular dysfunction.
• Identifying reliable biomarkers is crucial for diagnosis, prognosis, and monitoring treatment response in SSc.
• Endothelial cells, lymphocytes, and fibroblasts play key roles in SSc pathogenesis.

Purpose of the Study:

• To review and evaluate candidate biomarkers for endothelial cell, lymphocyte, and fibroblast function in systemic sclerosis.
• To determine the current status and future directions for biomarker discovery in SSc.

Main Methods:

• A comprehensive literature review was conducted on studies investigating biomarkers in systemic sclerosis.
• Candidate markers related to endothelial cell, lymphocyte, and fibroblast function were systematically analyzed.
• The utility and validation status of various markers were assessed.

Main Results:

• Autoantibody measurement and general inflammatory markers are considered minimum requirements for SSc biomarker assessment.
• Several other candidate markers for endothelial cell, lymphocyte, and fibroblast function require further investigation and validation.
• The review highlights the need for standardized assays and robust clinical validation.

Conclusions:

• Current evidence supports autoantibodies and general inflammatory markers as foundational for SSc biomarker panels.
• Further research is essential to validate novel markers for specific cell types involved in SSc.
• Establishing a comprehensive biomarker strategy is critical for advancing SSc management.